

Margaret Rosenfeld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6274230/publications.pdf>

Version: 2024-02-01

208
papers

18,202
citations

15504

65
h-index

14759

127
g-index

210
all docs

210
docs citations

210
times ranked

12203
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing encounter-based and annualized chronic pseudomonas infection definitions in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 40-44.	0.7	3
2	Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 529-539.	5.6	147
3	ERS/ATS technical standard on interpretive strategies for routine lung function tests. <i>European Respiratory Journal</i> , 2022, 60, 2101499.	6.7	323
4	Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without <i>Pseudomonas aeruginosa</i> . <i>Annals of the American Thoracic Society</i> , 2022, 19, 1320-1327.	3.2	5
5	The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 669-678.	10.7	20
6	Club cell secretory protein and lung function in children with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 811-820.	0.7	8
7	Application of gap time analysis with flexible hazards to pulmonary exacerbations in the EPIC observational study. <i>Biometrical Journal</i> , 2022, , .	1.0	0
8	Building for the Future: Establishment of the Primary Ciliary Dyskinesia Foundation Clinical Registry. , 2022, , .		0
9	Progression of Upper Airway Manifestations in Primary Ciliary Dyskinesia Throughout Childhood. , 2022, , .		0
10	Accounting for population structure in genetic studies of cystic fibrosis. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100117.	1.7	1
11	Relationship Between Genotype/Ultrastructural Defect and Neonatal Respiratory Distress in Primary Ciliary Dyskinesia. , 2022, , .		0
12	Performance and Usability of a New Mobile Phone Application in Assessing Respiratory Rate in Pediatric Patients. , 2022, , .		0
13	Factors Associated with Abnormal Lung Function in Adolescents With and Without HIV in Nairobi, Kenya. , 2022, , .		0
14	COMBATing airway inflammation in infants with cystic fibrosis. <i>Lancet Respiratory Medicine</i> , 2022, , .	10.7	0
15	A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for <i>F508del-CFTR</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1239-1247.	5.6	13
16	Ivacaftor in Infants Aged 4 to \leq12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 585-593.	5.6	67
17	Survey and electronic health record-based medication use agreement in children with cystic fibrosis: A retrospective cross-sectional study. <i>International Journal of Paediatric Dentistry</i> , 2021, 31, 247-253.	1.8	0
18	Innovating and adapting in pediatric pulmonology and sleep medicine during the COVID-19 pandemic: ATS pediatric assembly web committee consensus statement for initial COVID-19 virtual response. <i>Pediatric Pulmonology</i> , 2021, 56, 539-550.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00208.	2.4	4
20	Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment. <i>Annals of the American Thoracic Society</i> , 2021, 18, 266-272.	3.2	8
21	S63â€¦lvacaftor in 4- to <6-month-old infants with cystic fibrosis and a gating mutation: results of a 2-part, single-arm, Phase 3 study. , 2021, , .		1
22	Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired <i>Pseudomonas Aeruginosa</i>. <i>Clinical Infectious Diseases</i> , 2021, 73, 987-993.	5.8	4
23	Inflammasome Genetic Variants, Macrophage Function, and Clinical Outcomes in Cystic Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 65, 157-166.	2.9	11
24	Therapies Used for Primary Ciliary Dyskinesia in North American Children. , 2021, , .		0
25	Upper Airway Manifestations of Primary Ciliary Dyskinesia During Childhood. , 2021, , .		0
26	Relationship Between Genotype and Laterality Defects in Primary Ciliary Dyskinesia. , 2021, , .		0
27	Severity of Neonatal Respiratory Distress and Future Lung Function in Children with Primary Ciliary Dyskinesia. , 2021, , .		0
28	Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations. <i>Clinical Infectious Diseases</i> , 2021, 73, 1589-1596.	5.8	10
29	Health workersâ€™ perspectives of a mobile health tool to improve diagnosis and management of paediatric acute respiratory illnesses in Uganda: a qualitative study. <i>BMJ Open</i> , 2021, 11, e049708.	1.9	11
30	Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 114-118.	0.7	7
31	Predictors of pulmonary exacerbation treatment in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 407-414.	0.7	15
32	Resilience in adolescents and young adults with cystic fibrosis: A pilot feasibility study of the promoting resilience in stress managementÂ¡intervention. <i>Pediatric Pulmonology</i> , 2020, 55, 638-645.	2.0	13
33	Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1590-1598.	3.2	8
34	Pediatric lung function testing during a pandemic: An international perspective. <i>Paediatric Respiratory Reviews</i> , 2020, 36, 106-108.	1.8	9
35	Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens. From an Association of Pulmonary, Critical Care, and Sleep Division Directors and American Thoracic Societyâ€™coordinated Task Force. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1343-1351.	3.2	47
36	Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. <i>Pediatric Pulmonology</i> , 2020, 55, 3400-3406.	2.0	8

#	ARTICLE	IF	CITATIONS
37	Comparison of Longitudinal Clinical Outcomes in Primary Ciliary Dyskinesia and Cystic Fibrosis. , 2020, , ,		0
38	Association of Genotype and Structural Lung Disease in a Cohort of Children with PCD. , 2020, , ,		0
39	Comparison of Multiple Breath Washout and Spirometry in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis and Healthy Controls. Annals of the American Thoracic Society, 2020, 17, 1085-1093.	3.2	25
40	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. The Cochrane Library, 2020, 2020, CD001912.	2.8	7
41	Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease by Ultrastructure Defect and Genotype. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 190-198.	5.6	116
42	The expanding phenotype of <i>OFD1</i>-related disorders: Hemizygous loss of a function variants in three patients with primary ciliary dyskinesia. Molecular Genetics & Genomic Medicine, 2019, 7, e911.	1.2	31
43	Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine, the, 2019, 7, 802-809.	10.7	89
44	Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e70-e88.	5.6	1,812
45	Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 751-761.	2.1	0
46	Tidal Changes in Respiratory Resistance in Children with Cystic Fibrosis. , 2019, , ,		0
47	Palivizumab and Long-term Outcomes in Cystic Fibrosis. Pediatrics, 2019, 144, e20183495.	2.1	4
48	Socioeconomic and Environmental Risk Factors for Pediatric Asthma in an American Indian Community. Academic Pediatrics, 2019, 19, 631-637.	2.0	8
49	An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). Journal of Cystic Fibrosis, 2019, 18, 838-843.	0.7	94
50	Climate change and lung health: presidential failure, professional responsibility. Thorax, 2019, 74, 627-628.	5.6	1
51	Associating antimicrobial susceptibility testing with clinical outcomes in cystic fibrosis: More rigor and less frequency?. Journal of Cystic Fibrosis, 2019, 18, 159-160.	0.7	1
52	Sensitivity of Multiple Breath Washout and Spirometry for Detection of Early Lung Disease in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis: A Multicenter Study. , 2019, , ,		0
53	Initial Development of a Mobile Health Tool to Objectively Measure Respiratory Distress in Infants. , 2019, , ,		1
54	Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. Journal of Pediatrics, 2019, 215, 164-171.e2.	1.8	16

#	ARTICLE	IF	CITATIONS
55	Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens. <i>Annals of the American Thoracic Society</i> , 2018, 15, 702-709.	3.2	28
56	Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, e1-e19.	5.6	92
57	Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 526-528.	5.6	32
58	Initial development and pilot testing of observer-reported outcomes (ObsROs) for children with cystic fibrosis ages 0â€“11 years. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 680-686.	0.7	10
59	Treating Cystic Fibrosis Pulmonary Exacerbations: In the Hospital with a Physician or at Home under Your Own Supervision?. <i>Annals of the American Thoracic Society</i> , 2018, 15, 169-170.	3.2	0
60	Reply to Johnson: Improve Pulmonary Function Test Reporting. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 138-139.	5.6	0
61	Spirometry-Assisted High Resolution Chest Computed Tomography in Children: Is it Worth the Effort?. <i>Current Problems in Diagnostic Radiology</i> , 2018, 47, 14-18.	1.4	6
62	Risk Factors for Gaps in Care during Transfer from Pediatric to Adult Cystic Fibrosis Programs in the United States. <i>Annals of the American Thoracic Society</i> , 2018, 15, 234-240.	3.2	37
63	Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2018, 15, 42-48.	3.2	24
64	Longitudinal development of initial, chronic and mucoid <i>Pseudomonas aeruginosa</i> infection in young children with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 341-347.	0.7	38
65	Primary ciliary dyskinesia: keep it on your radar. <i>Thorax</i> , 2018, 73, 101-102.	5.6	5
66	Age-related heterogeneity in dental caries and associated risk factors in individuals with cystic fibrosis ages 6â€“20 years: A pilot study. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 747-759.	0.7	9
67	Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, e24-e39.	5.6	285
68	Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 545-553.	10.7	205
69	Azithromycin for Early <i>Pseudomonas</i> Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1177-1187.	5.6	75
70	Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis. <i>Pediatrics</i> , 2017, 139, .	2.1	52
71	Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations. <i>Pediatrics</i> , 2017, 139, .	2.1	48
72	Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. <i>Journal of Pediatrics</i> , 2017, 181, S4-S15.e1.	1.8	572

#	ARTICLE	IF	CITATIONS
73	Climate change and lung health: the challenge for a new president. <i>Thorax</i> , 2017, 72, 295-296.	5.6	5
74	Diagnosis of Cystic Fibrosis in Screened Populations. <i>Journal of Pediatrics</i> , 2017, 181, S33-S44.e2.	1.8	82
75	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. <i>The Cochrane Library</i> , 2017, 4, CD001912.	2.8	33
76	<i>Pseudomonas aeruginosa</i> eradication: Finally moving the needle?. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 309-310.	0.7	0
77	Accuracy of Nasal Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia: A Systematic Review and Meta-Analysis. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1184-1196.	3.2	41
78	Elementary, My Dear Watson! The Accumulating Evidence for the Lung Clearance Index in Monitoring Early Cystic Fibrosis Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1131-1132.	5.6	3
79	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 557-567.	10.7	243
80	S96–An open-label extension (ext) study of lumacaftor/ivacaftor (lum/iva) therapy in patients aged 6 to 11 years with cystic fibrosis (cf) homozygous for f508del-cftr. , 2017, , .		0
81	Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1463-1472.	5.6	450
82	Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis. <i>BMC Infectious Diseases</i> , 2017, 17, 411.	2.9	16
83	Lumacaftor/ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for <i>F508del-CFTR</i>. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 912-920.	5.6	138
84	Air pollution exposure is associated with MRSA acquisition in young U.S. children with cystic fibrosis. <i>BMC Pulmonary Medicine</i> , 2017, 17, 106.	2.0	30
85	Association of meteorological and geographical factors and risk of initial <i>Pseudomonas aeruginosa</i> acquisition in young children with cystic fibrosis. <i>Epidemiology and Infection</i> , 2016, 144, 1075-1083.	2.1	19
86	Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 386-391.	0.7	13
87	Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1305-1313.	3.2	138
88	Cystic Fibrosis Diagnosis and Newborn Screening. <i>Pediatric Clinics of North America</i> , 2016, 63, 599-615.	1.8	35
89	Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. <i>Lancet Respiratory Medicine</i> , 2016, 4, 107-115.	10.7	284
90	Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. <i>Pediatric Pulmonology</i> , 2016, 51, 115-132.	2.0	297

#	ARTICLE	IF	CITATIONS
91	Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. <i>Pediatrics</i> , 2016, 137, .	2.1	140
92	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. <i>Journal of Pediatrics</i> , 2016, 169, 116-121.e2.	1.8	44
93	An Official American Thoracic Society/European Respiratory Society Workshop Report: Evaluation of Respiratory Mechanics and Function in the Pediatric and Neonatal Intensive Care Units. <i>Annals of the American Thoracic Society</i> , 2016, 13, S1-S11.	3.2	29
94	Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. <i>Journal of Pediatrics</i> , 2015, 167, 1081-1088.e1.	1.8	63
95	Yoga as a Therapy for Adolescents and Young Adults with Cystic Fibrosis: A Pilot Study. <i>Global Advances in Health and Medicine</i> , 2015, 4, 32-36.	1.6	5
96	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2015, 50, 856-862.	2.0	19
97	Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2015, 50, 763-770.	2.0	94
98	Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. <i>Annals of the American Thoracic Society</i> , 2015, 12, 932-939.	3.2	96
99	Clinical Features of Childhood Primary Ciliary Dyskinesia by Genotype and Ultrastructural Phenotype. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 316-324.	5.6	214
100	Pulmonary exacerbations and parent-reported outcomes in children <6 years with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2015, 50, 236-243.	2.0	19
101	Fine Particulate Matter Exposure and Initial <i>Pseudomonas aeruginosa</i> Acquisition in Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 385-391.	3.2	57
102	WS01.5 An open-label study of the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2 to 5 years with cystic fibrosis and a CFTR gating mutation: The KIWI study. <i>Journal of Cystic Fibrosis</i> , 2015, 14, S2.	0.7	6
103	Impact of Sustained Eradication of New <i>Pseudomonas aeruginosa</i> Infection on Long-term Outcomes in Cystic Fibrosis. <i>Clinical Infectious Diseases</i> , 2015, 61, 707-715.	5.8	66
104	Initial evaluation of the Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) in infants and young children. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 403-411.	0.7	23
105	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site. <i>Pediatric Pulmonology</i> , 2015, 50, 431-440.	2.0	43
106	Outcomes of Infants With Indeterminate Diagnosis Detected by Cystic Fibrosis Newborn Screening. <i>Pediatrics</i> , 2015, 135, e1386-e1392.	2.1	78
107	Early Childhood Risk Factors for Decreased FEV1 at Age 6-7 Years in Young Children with Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 150819115840007.	3.2	25
108	Clinical outcomes after initial <i>pseudomonas</i> acquisition in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2015, 50, 42-48.	2.0	59

#	ARTICLE	IF	CITATIONS
109	Selection and Appropriate Use of Spirometric Reference Equations for the Pediatric Population. <i>Respiratory Medicine</i> , 2015, , 181-193.	0.1	0
110	Mutations in <i>RSPH1</i> Cause Primary Ciliary Dyskinesia with a Unique Clinical and Ciliary Phenotype. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 707-717.	5.6	191
111	Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic Approaches to Prevention and Eradication of Initial <i>Pseudomonas aeruginosa</i> Infection. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1640-1650.	3.2	197
112	Narrowing in on Early Cystic Fibrosis Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1082-1084.	5.6	5
113	Few Patient, Treatment, and Diagnostic or Microbiological Factors, Except Complications and Intermittent Negative Cerebrospinal Fluid (CSF) Cultures During First CSF Shunt Infection, Are Associated With Reinfection. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2014, 3, 15-22.	1.3	14
114	Laterality Defects Other Than Situs Inversus Totalis in Primary Ciliary Dyskinesia. <i>Chest</i> , 2014, 146, 1176-1186.	0.8	192
115	Survey of clinical infant lung function testing practices. <i>Pediatric Pulmonology</i> , 2014, 49, 126-131.	2.0	32
116	Early childhood wheezing is associated with lower lung function in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2014, 49, 745-750.	2.0	21
117	Differential Geographical Risk of Initial <i>Pseudomonas aeruginosa</i> Acquisition in Young US Children With Cystic Fibrosis. <i>American Journal of Epidemiology</i> , 2014, 179, 1503-1513.	3.4	22
118	Evaluation of Microbial Bacterial and Fungal Diversity in Cerebrospinal Fluid Shunt Infection. <i>PLoS ONE</i> , 2014, 9, e83229.	2.5	21
119	Cri du Chat Syndrome and Primary Ciliary Dyskinesia: A Common Genetic Cause on Chromosome 5p. <i>Journal of Pediatrics</i> , 2014, 165, 858-861.	1.8	15
120	Serology as a diagnostic tool for predicting initial <i>Pseudomonas aeruginosa</i> acquisition in children with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 542-549.	0.7	15
121	The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF Registry. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 319-327.	0.7	41
122	<i>Pseudomonas aeruginosa</i> Phenotypes Associated With Eradication Failure in Children With Cystic Fibrosis. <i>Clinical Infectious Diseases</i> , 2014, 59, 624-631.	5.8	64
123	<i>Pseudomonas aeruginosa</i> In Vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 289-297.	5.6	113
124	Season is associated with <i>Pseudomonas aeruginosa</i> acquisition in young children with cystic fibrosis. <i>Clinical Microbiology and Infection</i> , 2013, 19, E483-E489.	6.0	41
125	Exome Sequencing Identifies Mutations in <i>CCDC114</i> as a Cause of Primary Ciliary Dyskinesia. <i>American Journal of Human Genetics</i> , 2013, 92, 99-106.	6.2	138
126	<i>ZMYND10</i> Is Mutated in Primary Ciliary Dyskinesia and Interacts with <i>LRRC6</i> . <i>American Journal of Human Genetics</i> , 2013, 93, 336-345.	6.2	183

#	ARTICLE	IF	CITATIONS
127	Zebrafish Ciliopathy Screen Plus Human Mutational Analysis Identifies C21orf59 and CCDC65 Defects as Causing Primary Ciliary Dyskinesia. <i>American Journal of Human Genetics</i> , 2013, 93, 672-686.	6.2	184
128	Tracking lung function on any phone. , 2013, , .		22
129	Sputum Tobramycin Concentrations in Cystic Fibrosis Patients with Repeated Administration of Inhaled Tobramycin. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2013, 26, 69-75.	1.4	39
130	<i>Pseudomonas aeruginosa</i> serology and risk for re-isolation in the EPIC trial. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 147-153.	0.7	30
131	ARMC4 Mutations Cause Primary Ciliary Dyskinesia with Randomization of Left/Right Body Asymmetry. <i>American Journal of Human Genetics</i> , 2013, 93, 357-367.	6.2	150
132	Opportunities and pitfalls of registry data for clinical research. <i>Paediatric Respiratory Reviews</i> , 2013, 14, 141-145.	1.8	18
133	Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. <i>Contemporary Clinical Trials</i> , 2013, 36, 99-105.	1.8	8
134	An Official American Thoracic Society Workshop Report: Optimal Lung Function Tests for Monitoring Cystic Fibrosis, Bronchopulmonary Dysplasia, and Recurrent Wheezing in Children Less Than 6 Years of Age. <i>Annals of the American Thoracic Society</i> , 2013, 10, S1-S11.	3.2	155
135	Standardizing Nasal Nitric Oxide Measurement as a Test for Primary Ciliary Dyskinesia. <i>Annals of the American Thoracic Society</i> , 2013, 10, 574-581.	3.2	222
136	Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?. <i>European Respiratory Journal</i> , 2013, 42, 527-538.	6.7	49
137	Lung function from infancy to preschool in a cohort of children with cystic fibrosis. <i>European Respiratory Journal</i> , 2013, 41, 60-66.	6.7	21
138	Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. <i>Thorax</i> , 2013, 68, 643-651.	5.6	83
139	Lung Clearance Index as an Outcome Measure for Clinical Trials in Young Children with Cystic Fibrosis. A Pilot Study Using Inhaled Hypertonic Saline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 456-460.	5.6	147
140	Association of lung function, chest radiographs and clinical features in infants with cystic fibrosis. <i>European Respiratory Journal</i> , 2013, 42, 1545-1552.	6.7	23
141	Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease?. <i>European Respiratory Journal</i> , 2013, 42, 844-857.	6.7	36
142	Small airway involvement in cystic fibrosis lung disease: Routine spirometry as an early and sensitive marker. <i>Pediatric Pulmonology</i> , 2013, 48, 1081-1088.	2.0	33
143	Mutations in <i>CCDC39</i> and <i>CCDC40</i> are the Major Cause of Primary Ciliary Dyskinesia with Axonemal Disorganization and Absent Inner Dynein Arms. <i>Human Mutation</i> , 2013, 34, 462-472.	2.5	176
144	Standard care versus protocol based therapy for new onset <i>Pseudomonas aeruginosa</i> in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2013, 48, 943-953.	2.0	31

#	ARTICLE	IF	CITATIONS
145	Association of intraventricular hemorrhage secondary to prematurity with cerebrospinal fluid shunt surgery in the first year following initial shunt placement. <i>Journal of Neurosurgery: Pediatrics</i> , 2012, 9, 54-63.	1.3	34
146	Mutations of <i>DNAH11</i> in patients with primary ciliary dyskinesia with normal ciliary ultrastructure. <i>Thorax</i> , 2012, 67, 433-441.	5.6	198
147	Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2269-77.	7.4	175
148	Revision Surgeries Are Associated With Significant Increased Risk of Subsequent Cerebrospinal Fluid Shunt Infection. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 551-556.	2.0	51
149	Risk factors for age at initial <i>Pseudomonas</i> acquisition in the cystic fibrosis epic observational cohort. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 446-453.	0.7	78
150	Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 456-457.	0.7	28
151	SpiroSmart. , 2012, , .		154
152	Initial <i>Pseudomonas aeruginosa</i> treatment failure is associated with exacerbations in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2012, 47, 125-134.	2.0	78
153	Lung function distinguishes preschool children with CF from healthy controls in a multi-center setting. <i>Pediatric Pulmonology</i> , 2012, 47, 597-605.	2.0	41
154	Analysis of the associations between lung function and clinical features in preschool children with Cystic Fibrosis. <i>Pediatric Pulmonology</i> , 2012, 47, 574-581.	2.0	32
155	Emergence of Oseltamivir-Resistant Pandemic H1N1 in an Immunocompetent Child with Severe Status Asthmaticus. <i>Journal of Asthma</i> , 2011, 48, 572-575.	1.7	2
156	Treatment and Microbiology of Repeated Cerebrospinal Fluid Shunt Infections in Children. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 731-735.	2.0	40
157	Pulmonary exacerbations are associated with subsequent FEV ₁ decline in both adults and children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2011, 46, 393-400.	2.0	211
158	Diagnostic yield of nasal scrape biopsies in primary ciliary dyskinesia: A multicenter experience. <i>Pediatric Pulmonology</i> , 2011, 46, 483-488.	2.0	52
159	Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. <i>Pediatric Pulmonology</i> , 2011, 46, 666-671.	2.0	28
160	Accurate and privacy preserving cough sensing using a low-cost microphone. , 2011, , .		152
161	Bronchiectasis and Pulmonary Exacerbations in Children and Young Adults With Cystic Fibrosis. <i>Chest</i> , 2011, 140, 178-185.	0.8	66
162	Monitoring of Structure and Function in Early Cystic Fibrosis Lung Disease. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2011, 24, 133-137.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Appropriate Pediatric Spirometry Reference Equations and Interpretation. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2011, 24, 63-68.	0.8	2
164	Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early <i>Pseudomonas aeruginosa</i> Infection in Children With Cystic Fibrosis. <i>JAMA Pediatrics</i> , 2011, 165, 847.	3.0	199
165	Therapeutic bilateral lung lavage in a child with pulmonary alveolar proteinosis. <i>Pediatric Critical Care Medicine</i> , 2010, 11, e28-e31.	0.5	4
166	Return of FEV ₁ after pulmonary exacerbation in children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2010, 45, 127-134.	2.0	120
167	Cystic fibrosis lung disease starts in the small airways: Can we treat it more effectively?. <i>Pediatric Pulmonology</i> , 2010, 45, 107-117.	2.0	161
168	Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort. <i>Pediatric Pulmonology</i> , 2010, 45, 934-944.	2.0	51
169	Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 627-632.	5.6	445
170	Multicenter Evaluation of Infant Lung Function Tests as Cystic Fibrosis Clinical Trial Endpoints. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1387-1397.	5.6	90
171	Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis. <i>Journal of Pediatrics</i> , 2009, 155, S73-S93.	1.8	360
172	Cystic Fibrosis Foundation Practice Guidelines for the Management of Infants with Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome during the First Two Years of Life and Beyond. <i>Journal of Pediatrics</i> , 2009, 155, S106-S116.	1.8	176
173	Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,. <i>Contemporary Clinical Trials</i> , 2009, 30, 256-268.	1.8	110
174	Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations. <i>Pediatric Pulmonology</i> , 2008, 43, 1142-1146.	2.0	13
175	Respiratory Manifestations. , 2008, , 871-887.		1
176	An Overview of Endpoints for Cystic Fibrosis Clinical Trials: One Size Does Not Fit All. <i>Proceedings of the American Thoracic Society</i> , 2007, 4, 299-301.	3.5	48
177	Guidelines for Implementation of Cystic Fibrosis Newborn Screening Programs: Cystic Fibrosis Foundation Workshop Report. <i>Pediatrics</i> , 2007, 119, e495-e518.	2.1	139
178	Endpoints for Clinical Trials in Young Children with Cystic Fibrosis. <i>Proceedings of the American Thoracic Society</i> , 2007, 4, 418-430.	3.5	71
179	Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. <i>Genetics in Medicine</i> , 2007, 9, 695-704.	2.4	42
180	Approach to eradication of initial <i>Pseudomonas aeruginosa</i> infection in children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2007, 42, 751-756.	2.0	60

#	ARTICLE	IF	CITATIONS
181	Cystic fibrosis pulmonary exacerbations. <i>Journal of Pediatrics</i> , 2006, 148, 259-264.	1.8	139
182	Potential impact of newborn screening for cystic fibrosis on child survival: A systematic review and analysis. <i>Journal of Pediatrics</i> , 2006, 149, 362-366.	1.8	98
183	Cystic Fibrosis Disease-specific Centiles in 2000 and 2005. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1047a-1047a.	5.6	0
184	The Prevalence of Ibuprofen-sensitive Asthma in Children: A Randomized Controlled Bronchoprovocation Challenge Study. <i>Journal of Pediatrics</i> , 2005, 147, 233-238.	1.8	55
185	Overview of published evidence on outcomes with early diagnosis from large US observational studies. <i>Journal of Pediatrics</i> , 2005, 147, S11-S14.	1.8	34
186	Disease-specific Reference Equations for Lung Function in Patients with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 885-891.	5.6	65
187	Update on cystic fibrosis epidemiology. <i>Current Opinion in Pulmonary Medicine</i> , 2004, 10, 510-514.	2.6	42
188	Improved survival among young patients with cystic fibrosis. <i>Journal of Pediatrics</i> , 2003, 142, 631-636.	1.8	116
189	Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 841-849.	5.6	300
190	<i>Pseudomonas</i> acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. <i>Current Opinion in Pulmonary Medicine</i> , 2003, 9, 492-497.	2.6	109
191	Efficiency of Pulmonary Administration of Tobramycin Solution for Inhalation in Cystic Fibrosis Using an Improved Drug Delivery System. <i>Chest</i> , 2003, 123, 28-36.	0.8	76
192	Developing Cystic Fibrosis Lung Transplant Referral Criteria Using Predictors of 2-Year Mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 1550-1555.	5.6	255
193	<i>Pseudomonas aeruginosa</i> and other predictors of mortality and morbidity in young children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2002, 34, 91-100.	2.0	910
194	Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough?. <i>Journal of Hospital Infection</i> , 2001, 49, 229-230.	2.9	31
195	Defining a pulmonary exacerbation in cystic fibrosis. <i>Journal of Pediatrics</i> , 2001, 139, 359-365.	1.8	265
196	Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. <i>Journal of Pediatrics</i> , 2001, 139, 572-577.	1.8	73
197	Effect of choice of reference equation on analysis of pulmonary function in cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2001, 31, 227-237.	2.0	57
198	Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis*. <i>Pediatric Pulmonology</i> , 2001, 32, 356-366.	2.0	361

#	ARTICLE	IF	CITATIONS
199	Longitudinal Assessment of <i>Pseudomonas aeruginosa</i> in Young Children with Cystic Fibrosis. <i>Journal of Infectious Diseases</i> , 2001, 183, 444-452.	4.0	520
200	Nutritional Effects of Long-Term Gastrostomy Feedings in Children With Cystic Fibrosis. <i>Journal of the American Dietetic Association</i> , 1999, 99, 191-194.	1.1	58
201	Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. , 1999, 28, 321-328.		306
202	Home nebulizer use among patients with cystic fibrosis. <i>Journal of Pediatrics</i> , 1998, 132, 125-131.	1.8	59
203	AEROSOLIZED ANTIBIOTICS FOR BACTERIAL LOWER AIRWAY INFECTIONS. <i>Infectious Diseases in Clinical Practice</i> , 1998, 7, 66-79.	0.3	6
204	Aerosolized Antibiotics for Bacterial Lower Airway Infections. <i>Clinical Pulmonary Medicine</i> , 1997, 4, 101-112.	0.3	7
205	Gender Gap in Cystic Fibrosis Mortality. <i>American Journal of Epidemiology</i> , 1997, 145, 794-803.	3.4	335
206	Evolution of airway microbiology in the infant with cystic fibrosis: role of nonpseudomonal and pseudomonal pathogens. <i>Seminars in Respiratory Infections</i> , 1992, 7, 158-67.	1.3	12
207	Transcriptional and Post-Transcriptional Strategies in Neuroendocrine Gene Expression. , 1988, 5, 317-334.		0
208	Identification of Human Glucocorticoid Receptor Complementary DNA Clones by Epitope Selection. <i>Science</i> , 1985, 228, 740-742.	12.6	286